Bio-Rad expands exact diagnostics branded molecular portfolio with CT/NG positive and STI negative run controls

Oct. 31, 2022
News from Bio-Rad.

Bio-Rad Laboratories has further expanded its offering of molecular quality controls with the launch of two new Exact Diagnostics branded products: CT/NG Positive Run Control, intended to be used with Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) molecular assays; and STI Negative Run Control, which monitors the absence of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) in various molecular assays and can be used to detect errors in laboratory testing procedures including potential contamination events, while controlling for sample adequacy assessment. Both are external quality controls designed to be used with molecular assays to monitor their intra- and inter-run performance.   

The Exact Diagnostics CT/NG Positive Run Control contains a mix of formalin-inactivated whole CT elementary bodies with heat-inactivated whole NG microorganisms and is formulated in a synthetic matrix. The product is internally value assigned using Bio-Rad Droplet Digital PCR (ddPCR).   

The Exact Diagnostics STI Negative Run Control is a formulated synthetic matrix containing human cells. The human cells simulate adequate specimen sampling, which is tested by some assays. This product may also be used to dilute or spike-in patient specimens or analyte-containing materials for purposes such as assay validation and verification.  

Visit Bio-Rad for more news